The FDA report on vorapaxar in the elderly: A convoluted dilemma

International Journal of Cardiology

Volumn 201, Issue , 2015, Pages 601-603

  Serebruany, Victor L ^a   Fortmann, Seth D ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HeartDrug Research Laboratories   (United States)

Author keywords

Age; Bleeding; Clinical trials; Efficacy; Elderly; Vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; VORAPAXAR; LACTONE; PYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; AGE; AGED; BLEEDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

ACUTE CORONARY SYNDROME; AGED; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, PAR-1; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84943525488     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.08.177     Document Type: Editorial

References (11)

1. T. Kosoglou, L. Reyderman, R.G. Tiessen, A.A. van Vliet, R.R. Fales, R. Keller, B. Yang, and D.L. Cutler Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects Eur. J. Clin. Pharmacol. 68 2012 249 258
2. NDA 294-886 Cross-discipline Team Leader review on Vorapaxar April 18th, 2014 Available for download at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/204886Orig1s000SumR.pdf (Assessed May 15, 2015)
3. P. Tricoci, Z. Huang, C. Held, D.J. Moliterno, P.W. Armstrong, F. Van de Werf, H.D. White, P.E. Aylward, L. Wallentin, E. Chen, Y. Lokhnygina, J. Pei, S. Leonardi, T.L. Rorick, A.M. Kilian, L.H. Jennings, G. Ambrosio, C. Bode, A. Cequier, J.H. Cornel, R. Diaz, A. Erkan, K. Huber, M.P. Hudson, L. Jiang, J.W. Jukema, B.S. Lewis, A.M. Lincoff, G. Montalescot, J.C. Nicolau, H. Ogawa, M. Pfisterer, J.C. Prieto, W. Ruzyllo, P.R. Sinnaeve, R.F. Storey, M. Valgimigli, D.J. Whellan, P. Widimsky, J. Strony, R.A. Harrington, K.W. Mahaffey, and the TRACER Investigators Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N. Engl. J. Med. 366 2012 20 33
4. D.A. Morrow, E. Braunwald, M.P. Bonaca, and et al. Vorapaxar in the secondary prevention of atherothrombotic events N. Engl. J. Med. 366 2012 1404 1413
5. D. Mari, R. Coppola, and R. Provenzano Hemostasis factors and aging Exp. Gerontol. 43 2008 66 73
6. W.R. Wilkerson, and D.C. Sane Aging and thrombosis Semin. Thromb. Hemost 28 2002 555 568
7. S.G. Wannamethee, G.D.O. Lowe, P.H. Whincup, A. Rumley, M. Walker, and L. Lennon Physical activity and hemostatic and inflammatory variables in elderly men Circulation 105 2002 1785 1790
8. N.S. Abraham, C. Hartman, P. Richardson, D. Castillo, R.L. Street Jr., and A.D. Naik Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients Circulation 128 2013 1869 1877
9. M.T. Roe, S.G. Goodman, E.M. Ohman, S.R. Stevens, J.S. Hochman, S. Gottlieb, F. Martinez, A.J. Dalby, W.E. Boden, H.D. White, D. Prabhakaran, K.J. Winters, P.E. Aylward, J.P. Bassand, D.K. McGuire, D. Ardissino, K.A. Fox, and P.W. Armstrong Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel Circulation 128 2013 823 833
10. G.Y. Lip, N. Clementy, L. Pericart, A. Banerjee, and L. Fauchier Stroke and major bleeding risk in elderly patients aged 75 years with atrial fibrillation: the Loire Valley atrial fibrillation project Stroke 46 2015 143 150
11. V.L. Serebruany Redesigning TRACER trial after TRITON Int. J. Cardiol. 197 2015 44 47